Brief: Foghorn Therapeutics Highlights Clinical Program Updates

Foghorn Therapeutics

08/01/2024 13:25

Jan 8 (Reuters) - Foghorn Therapeutics Inc.  FHTX.O :
    * FOGHORN THERAPEUTICS HIGHLIGHTS CLINICAL PROGRAM UPDATES
AND
RESEARCH PROGRESS AND PROVIDES STRATEGIC OBJECTIVES FOR 2024
    * FOGHORN THERAPEUTICS INC. - FHD-286 COMBINATION STUDY IN
AML
CONTINUES TO PROGRESS IN CLINIC WITH DATA ANTICIPATED IN SECOND
HALF OF 2024
    * FOGHORN THERAPEUTICS - PRECLINICAL COMBINATION DATA WITH
FHD-286
AND TYROSINE KINASE INHIBITORS (TKIS) IN EGFR/KRAS RESISTANCE
ANTICIPATED BY Q2 2024
    * FOGHORN THERAPEUTICS- CASH, CASH EQUIVALENTS, AND
MARKETABLE
SECURITIES OF $259.9 MILLION, AS OF SEPT 30, PROVIDES CASH
RUNWAY INTO FIRST HALF OF 2026

Source text for Eikon:  ID:nGNX17Pbqq 
Further company coverage:  FHTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))